PEGylated Proteins Market (2026 - 2033)

PEGylated Proteins Market Summary

The global PEGylated proteins market size was valued at USD 1.8 billion in 2025 and is projected to grow from USD 2.0 billion in 2026 to USD 4.3 billion by 2033, at a CAGR of 11.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 34.0% in 2025. The growth is primarily driven by factors such as the rising incidence of degenerative & chronic diseases such as cancer, kidney disease, and rheumatoid arthritis; the growing demand for protein-based therapies; increased research activities for the development of novel therapeutics; and the advantages of PEGylated therapeutic proteins.

A rise in investments has been directly associated with increased research and development of novel vaccines, biologics, and diagnostics, along with the optimization of existing therapies. For instance, in May 2025, AbbVie announced that the U.S. FDA approved EMRELIS (telisotuzumab vedotin-tllv), an antibody-drug conjugate for the treatment of advanced non-small cell lung cancer. The approval reflects continued investment in biologics and targeted protein therapeutics, supporting innovation across biopharmaceutical development. Moreover, the use of PEGylated lipid nanoparticles in mRNA vaccines developed by Moderna and Pfizer-BioNTech has demonstrated the expanding role of PEG-based technologies in advanced drug delivery systems.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Advances in biotechnology and molecular biology have accelerated the development and adoption of protein-based therapeutics. The growing demand for vaccines, hormones, enzymes, growth factors, monoclonal antibodies, and other recombinant proteins has supported continued investment in biologics research and development. Their high specificity, improved therapeutic efficacy, and favorable safety profiles have contributed to the widespread adoption of biologic therapies. For instance, in March 2025, the U.S. FDA approved Qfitlia (fitusiran) from Sanofi for the routine prophylactic treatment of hemophilia A and B. The approval highlights continued regulatory support for advanced biologic therapies and reinforces investment in innovative therapeutic platforms. Continued regulatory approvals for biologic products are expected to accelerate research and development activities involving therapeutic proteins. In addition, leading pharmaceutical companies are increasing investments in biologics R&D to develop novel therapeutic approaches, improve drug delivery technologies, and expand treatment options for complex diseases.

PEGylated proteins offer several therapeutic advantages, including prolonged circulation time, enhanced molecular stability, improved aqueous solubility, and reduced dosing frequency. PEGylation also helps reduce the immunogenicity of many therapeutic proteins while improving their pharmacokinetic properties, resulting in better patient compliance and therapeutic outcomes. The successful integration of PEG molecules into biopharmaceuticals, coupled with ongoing advances in PEGylation technologies, is expected to further support the development of innovative long-acting therapeutics and drive market growth over the forecast period.

Analyst Perspective

The PEGylation proteins market continues to play a significant role in the development of biologics by improving the pharmacokinetic properties of therapeutic proteins and peptides, including extended half-life, enhanced stability, and reduced dosing frequency. Despite the emergence of alternative half-life extension and drug delivery technologies, PEGylation remains a well-established approach for enhancing the clinical performance of protein therapeutics in oncology, hematology, autoimmune disorders, and rare diseases. Increasing investments in biologics, biosimilars, protein therapeutics, and long-acting formulations continue to drive demand for PEGylation reagents and conjugation services across the pharmaceutical and biotechnology industries. Advances in site-specific PEGylation and protein engineering are improving product consistency, manufacturing efficiency, and therapeutic performance.

Product & Services Insights

The consumables segment dominated the global market in 2025, accounting for 63.0% of overall revenue. This dominance is attributed to the growing volume of research activities, expanding drug discovery and development programs, and increasing demand for advanced drug delivery systems, which drive the recurring use of PEGylation consumables such as activated PEG reagents, kits, and purification materials. In addition, the broad product portfolios offered by leading suppliers further support segment growth. The consumables segment is expected to maintain steady growth throughout the forecast period.

Continuous advancements in PEGylation technologies and the increasing demand for PEGylated therapeutics have accelerated the adoption of PEGylation consumables across research and commercial manufacturing. The versatile applications of PEG in protein engineering, drug development, and bioconjugation continue to support the widespread use of these products. Furthermore, companies offering custom PEG conjugation services and PEG-based products rely extensively on consumables for research, process development, and commercial manufacturing. The recurring demand for PEGylation reagents and other consumables throughout research, process optimization, and commercial production, together with the expanding availability of specialized PEGylation products, is expected to support sustained revenue growth of the consumables segment over the forecast period.

Protein Insights

The Colony-Stimulating Factors (CSFs) segment accounted for the highest revenue share in 2025, at 32.0%. CSFs are glycoproteins that bind to specific cell surface receptors and stimulate the proliferation, differentiation, and survival of hematopoietic progenitor cells into mature white blood cells. Clinically, CSFs are widely used to reduce the risk of chemotherapy-induced neutropenia and associated infections in cancer patients. The increasing global burden of cancer and the widespread use of myelosuppressive chemotherapy continue to drive demand for CSFs.

According to the International Agency for Research on Cancer (IARC), global cancer cases are projected to reach 27.5 million and cancer-related deaths 16.3 million by 2040. Moreover, companies continue to expand their portfolios of PEGylated therapeutics. For instance, in May 2026, the U.S. FDA approved ENNUMO (pegfilgrastim-pccg), Accord BioPharma's biosimilar to Neulasta (pegfilgrastim), for reducing the incidence of infection in patients receiving myelosuppressive chemotherapy. The approval reflects continued regulatory support for PEGylated G-CSF biosimilars and highlights ongoing product development opportunities within the CSF segment.

Application Insights

The cancer segment dominated the market in 2025 and is expected to register the fastest CAGR of 13.0% over the forecast period. The segment's dominance is attributed to the rising global incidence of cancer and the growing adoption of protein-based therapeutics in oncology. PEGylation has improved the pharmacokinetic properties of protein therapeutics by enhancing molecular stability, prolonging circulation time, reducing immunogenicity, and improving therapeutic efficacy, particularly in oncology applications. For instance, in June 2026, PharmaEssentia announced the U.S. FDA approval and commercial launch of the BESREMi Pen (ropeginterferon alfa-2b-njft) for adults with polycythemia vera. The prefilled pen offers a more convenient self-administration option while supporting the continued adoption of PEGylated protein therapeutics. According to the American Cancer Society's Cancer Statistics, 2025, an estimated 2,041,910 new cancer cases and 618,120 cancer-related deaths are projected to occur in the United States in 2025, highlighting the continued demand for effective protein-based therapeutics and advanced drug delivery technologies.

End Use Insights

The pharmaceutical & biotechnology companies segment accounted for the largest share, at 41.0% of overall revenue. This is attributed to expanding therapeutic pipelines, increasing investments in drug discovery and development, rising R&D expenditure, and supportive regulatory and government initiatives for biologics development. In addition, continued regulatory approvals for biologic and PEGylated therapeutics reinforce the leading role of pharmaceutical and biotechnology companies in the market. Growing demand for affordable and accessible biologic therapies continues to encourage pharmaceutical and biotechnology companies to increase R&D investments. Moreover, the patent expiry of several PEGylated therapeutics has intensified competition by creating opportunities for biosimilar development and encouraging new market entrants. These market opportunities have also promoted strategic partnerships, acquisitions, and industry consolidation among leading pharmaceutical and biotechnology companies.

Regional Insights

North America PEGylated Proteins Market Trends

The PEGylated proteinsindustry in North America dominated the global market in 2025, accounting for more than 34.0% of global revenue. The high prevalence of chronic diseases, increasing awareness of advanced biologic therapies, and strong healthcare infrastructure continue to support regional market growth. Well-established research infrastructure, significant investments in biologics research, and the presence of leading PEGylated protein manufacturers further contribute to market expansion. For instance, in November 2025, the U.S. Food and Drug Administration updated the prescribing information for ADYNOVATE, a PEGylated recombinant antihemophilic factor indicated for the treatment and routine prophylaxis of hemophilia A. The continued regulatory support for PEGylated therapeutics highlights the favorable commercialization environment and sustained adoption of advanced biologic therapies across North America.

To learn more about this report, Download Free Sample Report

Asia Pacific PEGylated Proteins Market Trends

The PEGylated proteinsindustry in Asia Pacific is expected to register the fastest CAGR over the forecast period. The region offers cost-effective manufacturing, clinical research, and biologics development capabilities, making it an attractive destination for biopharmaceutical companies. Cost-efficient research and manufacturing in countries such as India and China, coupled with advanced biopharmaceutical capabilities in Japan, are expected to support regional market growth. The growing geriatric population and rising demand for biologic and protein-based therapeutics for chronic diseases are further supporting market expansion. In addition, increasing government investments in biotechnology, biopharmaceutical manufacturing, and healthcare infrastructure are expected to accelerate market growth. For instance, in June 2025, AGC Biologics announced the expansion of its cell therapy process development and clinical manufacturing operations at the Yokohama Technical Center in Japan. The company also confirmed plans for a new manufacturing facility that is expected to provide commercial manufacturing services for mammalian-based protein biologics, cell therapies, and mRNA products by 2027.

Key PEGylated Proteins Company Insights

The industry is witnessing increasing consolidation as companies pursue acquisitions, partnerships, and collaborations to expand their product portfolios, strengthen bioprocessing capabilities, and enhance their competitive position. For instance, in September 2025, Thermo Fisher Scientific completed its acquisition of Solventum's Purification & Filtration business. The acquisition strengthened Thermo Fisher's bioprocessing portfolio by adding advanced filtration technologies that support the development and commercial manufacturing of biologics, including protein therapeutics, across upstream and downstream workflows. Such strategic initiatives expand the global presence of key players, enhance manufacturing capabilities, and intensify competition, thereby driving market growth.

Key PEGylated Proteins Companies:

The following key companies have been profiled for this study on the PEGylated proteins market.

• Thermo Fisher Scientific Inc.

• Abcam Limited

• JenKem Technology USA

• Merck KGaA

• Biosynth.

• Profacgen.

• Creative PEGWorks

• NOF AMERICA CORPORATION

• Aurigene Pharmaceutical Services Ltd.

• GANNET BIOCHEM

Recent Developments

• In May 2025, Nuclera and Cytiva announced a collaboration to accelerate drug discovery by integrating Nuclera's eProtein Discovery System with Cytiva's Biacore surface plasmon resonance (SPR) technology. The combined workflow enables protein production, purification, and characterization in as little as five days, streamlining protein-based drug research and development.

• In November 2024, Nektar Therapeutics entered into a definitive agreement with Ampersand Capital Partners to sell its commercial PEGylation reagent manufacturing business and manufacturing facility in Huntsville, Alabama. The transaction strengthens Ampersand's presence in PEG reagent manufacturing while ensuring continued commercial supply of PEGylation reagents for biopharmaceutical and PEGylated therapeutic applications.

Global PEGylated Proteins Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global PEGylated proteins market report based on product & services, protein, application, end use, and region:

• Product & Services Outlook (Revenue, USD Billion, 2021 - 2033)

  • Consumables

  • Services

• Protein Outlook (Revenue, USD Billion, 2021 - 2033)

  • Colony-stimulating Factor

  • Interferons

  • Erythropoietin

  • Recombinant Factor VII

  • Others

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Cancer

  • Autoimmune Diseases

  • Hepatitis

  • Multiple Sclerosis

  • Hemophilia

  • Gastrointestinal Disorders

  • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Contract Research Organizations

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE